{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:16:29Z","timestamp":1777482989078,"version":"3.51.4"},"reference-count":46,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This work was supported by the MUMC+\/VieCuri Science Funds"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,1,23]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>Shared decision-making improves patients\u2019 experiences with care, satisfaction with management decisions and possibly health outcomes. This study describes the development of a decision aid (DA) that supports patients with gout and their physicians in a face-to-face clinical setting to (a) decide whether or not to (re)start urate-lowering therapy (ULT) and (b) agree on the preferred ULT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Recommendations of the International Patient Decision Aid Standards group guided the development. A steering group of experts in gout and health services research specified the scope. Nominal group technique meetings were organised in which patients ranked the importance of preidentified potential characteristics\/attributes of ULT and discussed further needs regarding the DA. A literature search was conducted to collect evidence on gout outcomes with and without ULT. Subsequently, the DA prototype was designed and adjusted using feedback from the steering group and results of cognitive debriefing interviews among five gout patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The final DA consists of six pages. First, the DA clarifies the decision at stake and describes gout including its risk factors, the role of lifestyle and treatment of flares. Next, risk of future flares with and without ULT in relation to serum uric acid levels is described and visualised. Relevant attributes of ULT are presented in an option grid distinguishing first-line and second-line ULT. Finally, patients\u2019 believes and preferences are explicitly addressed before making the shared decision.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study provides initial support for usability of a DA for gout patients eligible for starting ULT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001979","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T02:55:27Z","timestamp":1645325727000},"page":"e001979","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-1444","authenticated-orcid":false,"given":"Ritch","family":"te Kampe","sequence":"first","affiliation":[{"name":"Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, Netherlands"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, Netherlands"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Jansen","sequence":"additional","affiliation":[{"name":"Rheumatology, VieCuri Medical Centre, Venlo, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"Janssen","sequence":"additional","affiliation":[{"name":"Rheumatology, VieCuri Medical Centre, Venlo, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein","family":"de Vries","sequence":"additional","affiliation":[{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands"},{"name":"Health Promotion, Maastricht University, Maastricht, Limburg, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"van Durme","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, Netherlands"},{"name":"Rheumatology, Centre Hospitalier Chr\u00e9tien, Liege, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"key":"2025090313015351000_8.1.e001979.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00346-9"},{"key":"2025090313015351000_8.1.e001979.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211472"},{"key":"2025090313015351000_8.1.e001979.3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.41067","article-title":"Population impact attributable to modifiable risk factors for hyperuricemia","volume":"72","author":"Choi","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090313015351000_8.1.e001979.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"2025090313015351000_8.1.e001979.5","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.semarthrit.2020.04.010","article-title":"Therapeutic approaches in the treatment of gout","volume":"50","author":"Pillinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313015351000_8.1.e001979.6","first-page":"27","article-title":"Gout: state of the art after a decade of developments","volume":"58","author":"Pascart","year":"2019","journal-title":"Rheumatology"},{"key":"2025090313015351000_8.1.e001979.7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/00325481.2016.1114878","article-title":"Management of gout in the real world: current practice versus guideline recommendations","volume":"128","author":"Doghramji","year":"2016","journal-title":"Postgrad Med"},{"key":"2025090313015351000_8.1.e001979.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2081-6"},{"key":"2025090313015351000_8.1.e001979.9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kex521","article-title":"Management of gout by UK rheumatologists: a British Society for rheumatology national audit","volume":"57","author":"Roddy","year":"2018","journal-title":"Rheumatology"},{"key":"2025090313015351000_8.1.e001979.10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00296-017-3777-3","article-title":"Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients","volume":"37","author":"Janssen","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025090313015351000_8.1.e001979.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex530"},{"key":"2025090313015351000_8.1.e001979.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3212-2"},{"key":"2025090313015351000_8.1.e001979.13","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S97927"},{"key":"2025090313015351000_8.1.e001979.14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10067-014-2838-1","article-title":"Health literacy in patients dealing with gout: a qualitative study","volume":"34","author":"van Onna","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090313015351000_8.1.e001979.15","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101051"},{"key":"2025090313015351000_8.1.e001979.16","first-page":"233","article-title":"Medscape's response to the Institute of medicine report: crossing the quality chasm: a new health system for the 21st century","volume":"3","author":"Leavitt","year":"2001","journal-title":"MedGenMed"},{"key":"2025090313015351000_8.1.e001979.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7464.507"},{"key":"2025090313015351000_8.1.e001979.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38926.629329.AE"},{"key":"2025090313015351000_8.1.e001979.19","doi-asserted-by":"crossref","first-page":"VAR-63","DOI":"10.1377\/hlthaff.var.63","article-title":"Modifying unwarranted variations in health care: shared decision making using patient decision AIDS","volume":"Variation","author":"O'Connor","year":"2004","journal-title":"Health Aff"},{"key":"2025090313015351000_8.1.e001979.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.zefq.2017.05.024","article-title":"Shared decision making in 2017: international accomplishments in policy, research and implementation","volume":"123-124","author":"H\u00e4rter","year":"2017","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"2025090313015351000_8.1.e001979.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1109283"},{"key":"2025090313015351000_8.1.e001979.22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001431.pub5"},{"key":"2025090313015351000_8.1.e001979.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2025090313015351000_8.1.e001979.24","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"2025090313015351000_8.1.e001979.25","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6947-13-S2-S2","article-title":"A systematic development process for patient decision AIDS","volume":"13 Suppl 2","author":"Coulter","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"2025090313015351000_8.1.e001979.26","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13501721"},{"key":"2025090313015351000_8.1.e001979.27","unstructured":"Delbecq AL , Van de Ven AH , Gustafson DH . Group techniques for program planning: a guide to nominal group and Delphi processes: Scott, Foresman, 1975."},{"key":"2025090313015351000_8.1.e001979.28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/PPA.S38408","article-title":"Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis","volume":"7","author":"Hiligsmann","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"2025090313015351000_8.1.e001979.29","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-016-0257-x"},{"key":"2025090313015351000_8.1.e001979.30","doi-asserted-by":"crossref","unstructured":"Seth R , Kydd ASR , Buchbinder R , et al . Allopurinol for chronic gout. Cochrane Database Syst Rev 2014;353.doi:10.1002\/14651858.CD006077.pub3","DOI":"10.1002\/14651858.CD006077.pub3"},{"key":"2025090313015351000_8.1.e001979.31","first-page":"CD010457","article-title":"Uricosuric medications for chronic gout","volume":"2014","author":"Kydd","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090313015351000_8.1.e001979.32","first-page":"CD008653","article-title":"Febuxostat for treating chronic gout","volume":"353","author":"Tayar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090313015351000_8.1.e001979.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7417.736"},{"key":"2025090313015351000_8.1.e001979.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181071"},{"key":"2025090313015351000_8.1.e001979.35","first-page":"163","article-title":"The Ottawa patient decision AIDS","volume":"2","author":"O'Connor","year":"1999","journal-title":"Eff Clin Pract"},{"key":"2025090313015351000_8.1.e001979.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"2025090313015351000_8.1.e001979.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.05.025"},{"key":"2025090313015351000_8.1.e001979.38","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology"},{"key":"2025090313015351000_8.1.e001979.39","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090313015351000_8.1.e001979.40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.40685","article-title":"Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313015351000_8.1.e001979.41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jbspin.2020.03.017","article-title":"Evaluation of febuxostat initiation during an acute gout attack: a prospective, randomized clinical trial","volume":"87","author":"Sun","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2025090313015351000_8.1.e001979.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160452"},{"key":"2025090313015351000_8.1.e001979.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"2025090313015351000_8.1.e001979.44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10067-020-05421-9","article-title":"Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice","volume":"40","author":"Singh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025090313015351000_8.1.e001979.45","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6947-13-S2-S7","article-title":"Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers","volume":"13 Suppl 2","author":"Trevena","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"2025090313015351000_8.1.e001979.46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/hex.13184","article-title":"Development of a novel gout treatment patient decision aid by patient and physician: a qualitative research study","volume":"24","author":"Meyappan","year":"2021","journal-title":"Health Expect"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:02:01Z","timestamp":1756929721000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,19]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/rmdopen-2021-001979"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001979","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}